Calendar Year Performance 2014Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023
-
-
-
-
-
-
-
-
-
+ 3.8 %
Net Asset Value
107.57 £
Asset Under Management
148 M €
Market
Global market
SFDR - Fund Classification
Article
8
Data as of: 6 Oct 2024.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
The sell-off seen on the equities markets at the start of the month finally paid off for the Merger Arbitrage strategy, as shown by the HFRX Merger Arbitrage index, which posted a monthly performance of +0.44%.
The phase of tightening Merger Arbitrage spreads that began at the beginning of July continued during the month with the finalisation of deals such as Cerevel Therapeutics in the US, L'Occitane International in Hong Kong and Redrow in the UK.
Some good news: Network International finally obtained all the necessary authorisations to close its acquisition by Brookfield, and Europe gave the go-ahead for Hewlett Packard's takeover of Juniper.
No deal failures to report
26 new deals were announced this month for a total of $81bn, slightly down on the same period last year
While M&A activity is slowing down a little in the US ahead of the elections, it remains buoyant in Europe and Asia (particularly Japan). We are also seeing the gradual return of private equity funds, which accounted for almost 25% of deals announced during the month.
Finally, we should mention a good deal announced in the US: the acquisition of Kellanova, the breakfast cereal manufacturer, by Mars for a total of $35 billion.
Performance commentary
The fund had a positive performance over the month.
Main positive contributors to performance were: Ansys, Catalent and Juniper.
Main negative contributors to performance were: Hess, Nuvei and Shinko Electric.
Outlook strategy
The fund's investment rate was 128%, up on the previous month.
With 57 positions in the portfolio, diversification remains satisfactory.
2024 should see a recovery in the M&A cycle, driven in particular by falling interest rates, the energy transition affecting many sectors of the economy, the return of private equity funds and changes to stock market regulations in Japan.
The risk premium of the Merger Arbitrage strategy currently offers investors returns that are still attractive, especially in an environment where deal failure rates remain low.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment